| Literature DB >> 25151398 |
Abilio Reig-Ferrer1, Rosario Ferrer-Cascales, Ana Santos-Ruiz, Adolfo Campos-Ferrer, Alvaro Prieto-Seva, Irene Velasco-Ruiz, Maria Dolores Fernandez-Pascual, Natalia Albaladejo-Blazquez.
Abstract
BACKGROUND: The aging process involves a decline in immune functioning that renders elderly people more vulnerable to disease. In residential programs for the aged, it is vital to diminish their risk of disease, promote their independence, and augment their psychological well-being and quality of life.Entities:
Mesh:
Year: 2014 PMID: 25151398 PMCID: PMC4153914 DOI: 10.1186/1472-6882-14-311
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Figure 1CONSORT flowchart of participants retained at each phase of the trial.
Means (M) and standard deviations (SD) of psychological measures for participants of both groups
| Variable | Group | A M ± SD | Mann-Whitney | B M ± SD | Mann-Whitney | C M ± SD | Mann-Whitney | Wilcoxon’s | Wilcoxon’s | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |||||
|
| TG | 16.46 ± 5.24 | -0.39 | 0.69 | 17.92 ± 3.71 | -0.34 | 0.72 | 16.91 ± 4.74 | -1.07 | 0.28 | -1.53 | 0.12 | 0.00 | 1.00 |
| CG | 17.80 ± 3.34 | 17.13 ± 5.17 | 18.93 ± 3.84 | -0.51 | 0.60 | -0.94 | 0.34 | |||||||
| Positive Affect | TG | 2.85 ± 1.34 | -1.85 | 0.06 | 2.54 ± 0.97 | -0.19 | 0.84 | 2.73 ± 1.10 | -0.62 | 0.53 | -0.78 | 0.43 | -0.99 | 0.31 |
| CG | 2.00 ± 1.11 | 2.40 ± 1.24 | 2.40 ± 1.24 | -1.22 | 0.22 | -1.23 | 0.21 | |||||||
| Negative Affect | TG | 3.15 ± 1.21 | -1.59 | 0.11 | 2.38 ± 0.96 | -0.55 | 0.58 | 3.00 ± 1.34 | -0.80 | 0.42 | -1.89 |
| -0.36 | 0.71 |
| CG | 2.36 ± 1.34 | 2.60 ± 1.12 | 2.60 ± 1.24 | -0.18 | 0.85 | -0.36 | 0.71 | |||||||
| Affect: | TG | -0.31 ± 1.60 | -0.47 | 0.63 | 0.15 ± 0.69 | -0.83 | 0.40 | -0.27 ± 0.90 | -0.29 | 0.76 | -0.99 | 0.32 | -0.66 | 0.50 |
| Hedonic balance | CG | -0.36 ± 1.39 | -0.20 ± 1.21 | -0.20 ± 1.08 | -0.85 | 0.39 | -0.55 | 0.58 | ||||||
| Affect: | TG | 4.69 ± 1.60 | -0.47 | 0.63 | 5.15 ± 0.69 | -0.83 | 0.40 | 4.73 ± 0.90 | -0.29 | 0.76 | -0.99 | 0.32 | -0.66 | 0.50 |
| Standardized ABS | CG | 4.64 ± 1.39 | 4.80 ± 1.21 | 4.80 ± 1.08 | -0.08 | 0.39 | -0.55 | 0.58 | ||||||
|
| ||||||||||||||
| Energy | TG | 1.77 ± 1.17 | -0.40 | 0.68 | 2.00 ± 1.15 | -0.92 | 0.35 | 1.36 ± 1.43 | -0.51 | 0.60 | -0.87 | 0.38 | -0.96 | 0.33 |
| CG | 1.53 ± 1.30 | 1.60 ± 1.12 | 1.53 ± 1.19 | -0.44 | 0.65 | 0.00 | 1.00 | |||||||
| Pain | TG | 3.62 ± 2.90 | -1.00 | 0.31 | 3.46 ± 3.10 | -0.67 | 0.49 | 2.91 ± 2.51 | -0.13 | 0.89 | -0.10 | 0.91 | -1.02 | 0.30 |
| CG | 2.60 ± 2.64 | 2.87 ± 3.27 | 3.00 ± 3.16 | -0.27 | 0.78 | -0.49 | 0.62 | |||||||
| Emotional | TG | 4.85 ± 1.68 | -2.01 |
| 3.54 ± 1.85 | -0.02 | 0.98 | 3.64 ± 2.98 | -0.18 | 0.85 | -2.22 |
| -1.79 | 0.07 |
| Reactions | CG | 3.53 ± 1.85 | 3.73 ± 2.31 | 3.13 ± 1.88 | -0.14 | 0.88 | -0.71 | 0.47 | ||||||
| Sleep | TG | 2.54 ± 1.56 | -0.46 | 0.63 | 2.46 ± 1.61 | -0.12 | 0.90 | 3.09 ± 1.30 | -1.36 | 0.17 | -0.58 | 0.56 | -1.41 | 0.15 |
| CG | 2.27 ± 1.67 | 2.53 ± 1.85 | 2.13 ± 1.92 | -1.15 | 0.24 | -0.43 | 0.66 | |||||||
| Social | TG | 1.23 ± 1.24 | -0.26 | 0.79 | 0.85 ± 0.99 | -0.53 | 0.59 | 0.91 ± 1.22 | -0.08 | 0.93 | -0.50 | 0.13 | -1.29 | 0.19 |
| Isolation | CG | 1.33 ± 1.23 | 1.27 ± 1.49 | 1.13 ± 1.46 | -0.06 | 0.95 | -0.88 | 0.37 | ||||||
| Physical | TG | 4.15 ± 2.12 | -0.81 | 0.41 | 4.31 ± 2.81 | -1.06 | 0.28 | 3.36 ± 2.46 | -0.07 | 0.93 | -0.41 | 0.68 | -1.93 |
|
| Mobility | CG | 3.67 ± 2.29 | 3.13 ± 2.67 | 3.33 ± 2.19 | -1.24 | 0.21 | -0.81 | 0.41 | ||||||
| NHP Total | TG | 18.15 ± 7.49 | -1.08 | 0.27 | 16.62 ± 8.33 | -0.43 | 0.66 | 15.27 ± 7.88 | -0.39 | 0.69 | -1.02 | 0.30 | -1.89 |
|
| CG | 14.93 ± 6.93 | 15.13 ± 9.78 | 14.27 ± 9.07 | -0.11 | 0.90 | -0.66 | 0.50 | |||||||
| Benson’s Five | TG | 2.85 ± 1.28 | -1.18 | 0.23 | 1.83 ± 1.03 | -0.40 | 0.68 | 2.36 ± 1.43 | -0.79 | 0.42 | -2.04 |
| -0.95 | 0.34 |
| Symptoms | CG | 2.27 ± 1.53 | 2.00 ± 1.20 | 1.87 ± 1.51 | -0.81 | 0.41 | -1.11 | 0.26 | ||||||
Note: Between-group comparisons (Mann–Whitney U test) at three assessment times; and within-subject analyses (Wilcoxon’s T) comparing pre-treatment assessment (A) with post-treatment assessment (B) and follow-up assessment (C). TG: Treatment Group; CG: Waitlist Control Group; M: Mean (SD: Standard Deviation); ABS: Affect Balance Scale; SWLS: Satisfaction with Life Scale; NHP: Nottingham Health Profile.
Bold text: p < 0.05.
Figure 2Weighted scores for the treatment group: Nottingham Health Profile at the three assessment times. A: pre-treatment assessment; B: post-treatment assessment; C: three-month follow-up assessment. E: Energy; P: Pain; ER: Emotional Reactions; S: Sleep; SI: Social Isolation; PM: Physical Mobility.
Prevalence of medical pathologies
| Treatment group | Control group | |
|---|---|---|
| Hypertension | 8 | 8 |
| Mood disorders | 7 | 4 |
| Sensory disorders | 5 | - |
| Musculoskeletal pathologies | 4 | 4 |
| Diabetes | 3 | 3 |
| Heart failure | 2 | 2 |
| COPD | 1 | - |
| Benign prostatic hyperplasia | 1 | - |
| Parkinson’s disease | 1 | - |
| Acute myocardial infarction | - | 1 |
| Pacemaker | - | 2 |
| Chronic renal failure | - | 2 |
| Previous stroke | - | 1 |
| Adrenal/thyroid insufficiency | - | 1 |
Note: COPD: Chronic Obstructive Pulmonary Disease.
Clinical measures of both groups at three assessment times
| Variable | Group | A M ± SD | Mann-Whitney | B M ± SD | Mann-Whitney | C M ± SD | Mann-Whitney | Wilcoxon’s | Wilcoxon’s | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |||||
| SBP (mmHg) | TG | 143.08 ± 21.65 | 0.00 | 1.00 | 138.08 ± 19.53 | -0.74 | 0.45 | 135.00 ± 19.16 | -0.66 | 0.51 | -0.90 | 0.36 | -1.63 | 0.10 |
| CG | 141.67 ± 19.88 | 144.44 ± 20.53 | 141.67 ± 17.22 | -0.77 | 0.43 | -0.63 | 0.52 | |||||||
| DBP (mmHg) | TG | 75.77 ± 12.72 | -0.37 | 0.70 | 74.62 ± 9.00 | -0.27 | 0.78 | 67.50 ± 9.57 | -1.26 | 0.20 | -0.27 | 0.78 | -1.13 | 0.25 |
| CG | 72.33 ± 10.33 | 75.56 ± 9.82 | 75.00 ± 8.37 | -0.43 | 0.66 | -0.13 | 0.89 | |||||||
| HR (bpm) | TG | 79.08 ± 12.12 | -0.95 | 0.34 | 80.09 ± 14.02 | -1.07 | 0.28 | - | - | - | -0.10 | 0.91 | - | - |
| CG | 73.27 ± 8.45 | 73.00 ± 7.35 | - | -0.35 | 0.72 | - | - | |||||||
| Leukocytes/mm3 | TG | 6646.15 ± 1145.73 | -0.29 | 0.77 | 6584.62 ± 1003.20 | -1.23 | 0.21 | 6180.00 ± 1139.98 | -0.78 | 0.43 | -0.52 | 0.60 | -1.63 | 0.10 |
| CG | 6450.00 ± 1399.31 | 6192.31 ± 1515.18 | 6861.54 ± 1526.18 | -0.35 | 0.72 | -0.39 | 0.69 | |||||||
| Segmented (%) | TG | 56.74 ± 7.70 | -0.34 |
| 56.38 ± 7.41 | -2.30 |
| 59.44 ± 7.77 | -1.67 | 0.09 | -0.17 | 0.86 | -1.07 | 0.28 |
| CG | 47.55 ± 11.31 | 48.93 ± 8.56 | 51.89 ± 10.34 | -1.05 | 0.28 | -1.29 | 0.19 | |||||||
| Limphocytes (%) | TG | 30.55 ± 7.90 | -1.82 | 0.06 | 30.66 ± 6.77 | -2.38 |
| 28.92 ± 6.80 | -1.36 | 0.17 | -0.14 | 0.88 | -0.81 | 0.41 |
| CG | 38.02 ± 12.50 | 36.99 ± 7.16 | 35.48 ± 10.73 | -0.15 | 0.87 | -0.31 | 0.75 | |||||||
| Monocytes (%) | TG | 8.63 ± 1.63 | -0.87 | 0.38 | 8.72 ± 1.92 | -0.61 | 0.53 | 9.12 ± 2.02 | -0.50 | 0.62 | 0.00 | 1.00 | -1.71 | 0.08 |
| CG | 9.67 ± 2.63 | 9.07 ± 1.99 | 8.72 ± 2.34 | -0.27 | 0.78 | -1.29 | 0.19 | |||||||
| Eosinophils (%) | TG | 3.56 ± 1.82 | -0.72 | 0.46 | 3.64 ± 2.00 | -0.64 | 0.52 | 3.64 ± 2.24 | -0.59 | 0.55 | 0.00 | 1.00 | -0.25 | 0.79 |
| CG | 4.15 ± 2.60 | 4.28 ± 2.61 | 3.96 ± 1.99 | -0.23 | 0.81 | -1.11 | 0.26 | |||||||
| Basophils (%) | TG | 0.50 ± 0.21 | -0.71 | 0.47 | 0.73 ± 0.58 | -0.31 | 0.75 | 0.48 ± 0.12 | -2.01 |
| -1.07 | 0.28 | -0.81 | 0.41 |
| CG | 0.58 ± 0.33 | 0.70 ± 0.43 | 0.69 ± 0.33 | -0.27 | 0.78 | -1.54 | 0.12 | |||||||
| Red blood (cells/mm3) | TG | 4.42 ± 0.33 | -1.05 | 0.29 | 4.49 ± 0.37 | -1.13 | 0.25 | 4.53 ± 0.38 | -1.34 | 0.17 | -0.80 | 0.42 | -1.68 | 0.09 |
| CG | 4.30 ± 0.39 | 4.36 ± 0.49 | 4.31 ± 0.35 | -1.29 | 0.19 | -0.39 | 0.69 | |||||||
| Hemoglobin (g/dl) | TG | 13.47 ± 1.18 | -1.43 | 0.15 | 13.61 ± 1.31 | -1.07 | 0.28 | 13.90 ± 1.20 | -1.40 | 0.16 | -0.87 | 0.38 | -2.19 |
|
| CG | 12.86 ± 1.28 | 13.04 ± 1.67 | 13.08 ± 1.17 | -0.93 | 0.35 | -1.33 | 0.18 | |||||||
| Hematocrit (%) | TG | 41.66 ± 3.57 | -1.67 |
| 41.75 ± 3.83 | -1.18 | 0.23 | 41.52 ± 3.81 | -0.59 | 0.55 | -0.24 | 0.80 | -0.15 | 0.87 |
| CG | 39.35 ± 3.71 | 39.82 ± 4.31 | 40.57 ± 3.42 | -0.90 | 0.36 | -1.41 | 0.15 | |||||||
| MCV (fl) | TG | 94.23 ± 4.53 | -1.62 | 0.10 | 93.40 ± 4.61 | -1.10 | 0.27 | 92.14 ± 4.41 | -1.18 | 0.23 | -2.62 |
| -2.49 |
|
| CG | 91.45 ± 5.27 | 91.80 ± 5.14 | 94.29 ± 6.01 | -0.49 | 0.62 | -1.86 | 0.06 | |||||||
| Platelets/mm3 | TG | 232.38 ± 49.53 | -1.57 | 0.11 | 234.77 ± 55.25 | -1.71 | 0.08 | 196.70 ± 37.78 | -0.12 | 0.90 | -0.38 | 0.70 | -2.14 |
|
| CG | 197.57 ± 41.64 | 197.00 ± 38.20 | 203.66 ± 62.30 | -0.66 | 0.50 | -0.15 | 0.87 | |||||||
| ESR (mm/h) | TG | 40.25 ± 21.93 | -0.69 | 0.48 | 44.55 ± 31.70 | 0.22 | 0.82 | 29.14 ± 18.84 | -0.76 | 0.44 | -0.77 | 0.44 | -0.94 | 0.34 |
| CG | 35.36 ± 27.54 | 45.29 ± 23.96 | 41.50 ± 29.78 | -0.63 | 0.52 | -0.44 | 0.65 | |||||||
| Glycemia (mg/dl) | TG | 108.08 ± 23.46 | -2.21 | 0.22 | 108.82 ± 31.59 | -0.60 | 0.54 | 102.0 ± 29.21 | -1.05 | 0.29 | -0.89 | 0.37 | -0.25 | 0.79 |
| CG | 91.53 ± 15.08 | 103.69 ± 47.89 | 86.54 ± 19.33 | -0.15 | 0.87 | -1.54 | 0.12 | |||||||
| Creatinine (mg/dl) | TG | 0.92 ± 0.18 | -0.87 | 0.38 | 0.92 ± 0.22 | -1.45 | 0.14 | 0.97 ± 0.19 | -1.68 | 0.09 | -0.71 | 0.47 | -2.00 |
|
| CG | 1.01 ± 0.30 | 0.99 ± 0.18 | 1.13 ± 0.36 | -1.45 | 0.14 | -2.74 |
| |||||||
| Urea (mg/dl) | TG | 34.23 ± 9.75 | -1.91 |
| 38.27 ± 6.39 | -1.62 | 0.10 | 41.09 ± 8.70 | -0.87 | 0.38 | -2.32 | 0.02 | -2.18 |
|
| CG | 6.87 ± 20.27 | 46.31 ± 12.43 | 51.46 ± 20.53 | -0.17 | 0.86 | -1.18 | 0.23 | |||||||
| Uric Acid (mg/dl) | TG | 4.58 ± 1.23 | -1.45 | 0.14 | 4.50 ± 1.55 | -1.59 | 0.11 | 4.75 ± 1.41 | -1.30 | 0.19 | -1.11 | 0.26 | -0.89 | 0.37 |
| CG | 5.58 ± 1.81 | 5.52 ± 1.40 | 5.57 ± 1.50 | -0.24 | 0.80 | -0.17 | 0.86 | |||||||
| Cholesterol (mg/dl) | TG | 196.46 ± 29.01 | -0.53 | 0.59 | 190.00 ± 35.79 | -1.04 | 0.29 | 215.64 ± 40.38 | -0.98 | 0.32 | -0.22 | 0.82 | -1.86 | 0.06 |
| CG | 202.93 ± 46.63 | 210.54 ± 47.76 | 202.15 ± 30.02 | -1.51 | 0.13 | -0.35 | 0.72 | |||||||
| HDL Cholesterol | TG | 51.50 ± 12.66 | -0.29 | 0.77 | 52.03 ± 13.29 | -0.23 | 0.81 | 55.19 ± 13.74 | -0.46 | 0.64 | -0.10 | 0.91 | -1.47 | 0.13 |
| (mg/dl) | CG | 53.00 ± 11.67 | 50.95 ± 9.66 | 56.35 ± 13.10 | -1.12 | 0.26 | -2.66 |
| ||||||
| Triglycerides (mg/dl) | TG | 135.46 ± 70.04 | -0.73 | 0.46 | 128.18 ± 68.05 | -0.40 | 0.68 | 137.36 ± 92.12 | -0.20 | 0.83 | -1.24 | 0.21 | -0.35 | 0.72 |
| CG | 126.20 ± 75.86 | 146.62 ± 95.11 | 104.00 ± 27.91 | -0.98 | 0.32 | -0.07 | 0.93 | |||||||
| LDL Cholesterol | TG | 117.86 ± 29.38 | -0.68 | 0.49 | 112.32 ± 31.70 | -1.04 | 0.29 | 131.47 ± 33.46 | -0.97 | 0.33 | 0.00 | 1.00 | -1.48 | 0.13 |
| (mg/dl) | CG | 130.77 ± 28.01 | 128.33 ± 36.95 | 125.32 ± 25.37 | -0.84 | 0.40 | -0.65 | 0.51 | ||||||
| AST (U/L) | TG | 22.37 ± 5.08 | -0.76 | 0.44 | 19.88 ± 5.97 | -0.66 | 0.50 | 26.90 ± 15.21 | -1.36 | 0.17 | -2.40 | 0.01 | -0.44 | 0.65 |
| CG | 21.49 ± 6.91 | 21.59 ± 5.90 | 19.99 ± 7.71 | -0.10 | 0.91 | -0.45 | 0.65 | |||||||
| ALT (U/L) | TG | 18.41 ± 4.85 | -0.96 | 0.33 | 15.72 ± 5.01 | -0.49 | 0.62 | 14.00 ± 5.50 | -0.78 | 0.43 | -2.84 | 0.04 | -1.95 |
|
| CG | 18.73 ± 12.10 | 18.90 ± 11.43 | 17.73 ± 9.72 | -0.59 | 0.55 | -1.01 | 0.31 | |||||||
| GGT (U/L) | TG | 19.93 ± 6.88 | -0.58 | 0.56 | 18.88 ± 3.90 | -0.63 | 0.52 | 19.23 ± 5.05 | -1.16 | 0.24 | -1.29 | 0.19 | -0.88 | 0.37 |
| CG | 32.14 ± 30.03 | 20.29 ± 14.50 | 39.80 ± 39.82 | -1.02 | 0.30 | -2.59 |
| |||||||
| Total proteins (gr/dl) | TG | 6.90 ± 0.48 | -1.24 | 0.21 | 6.90 ± 0.42 | -0.06 | 0.94 | 7.31 ± 0.42 | -0.03 | 0.97 | -1.13 | 0.25 | -2.19 |
|
| CG | 6.71 ± 0.48 | 6.88 ± 0.38 | 7.26 ± 0.34 | -1.49 | 0.13 | -2.90 |
| |||||||
| Albumin (gr/dl) | TG | 3.93 ± 0.32 | -0.09 | 0.92 | 3.87 ± 0.18 | -0.49 | 0.62 | 4.02 ± 0.18 | -0.76 | 0.44 | -0.17 | 0.85 | -0.05 | 0.95 |
| CG | 3.95 ± 0.30 | 3.82 ± 0.34 | 4.10 ± 0.26 | -0.80 | 0.42 | -1.33 | 0.18 | |||||||
Note: Between-group (Mann–Whitney U test) and within-subject (Wilcoxon’s T test) effects for clinical values at three assessment times. TG: Treatment Group; CG: Waitlist Control Group; M: Mean ± SD: Standard Deviation); SBP: Systolic Blood Pressure; DBP: Dyastolic Blood Pressure; HR: Heart Rate; MCV: Mean Corpuscular Volume; ESR: Erythrocyte Sedimentation Rate; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transferase; A: pre-treatment assessment; B: post-treatment assessment; C: three-month follow-up assessmen. Bold text: p < 0.05.
Immunological measures of both groups at three assessment times
| Variable | Group | A M ± SD | Mann–Whitney | B M ± SD | Mann–Whitney | C M ± SD | Mann–Whitney | Wilcoxon’s | Wilcoxon’s | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |||||
| CD19 | TG | 6.60 ± 2.53 | -0.23 | 0.81 | 4.86 ± 1.33 | -1.97 |
| 4.72 ± 3.60 | -0.80 | 0.41 | -2.43 |
| -1.95 |
|
| CG | 6.85 ± 1.74 | 6.75 ± 3.08 | 5.25 ± 2.49 | -0.17 | 0.86 | -1.76 | 0.07 | |||||||
| CD4 | TG | 41.43 ± 11.40 | -0.48 | 0.62 | 43.83 ± 6.67 | -0.66 | 0.50 | 51.90 ± 24.62 | -0.06 | 0.95 | -0.66 | 0.50 | -1.51 | 0.13 |
| CG | 40.36 ± 10.74 | 45.51 ± 9.15 | 47.83 ± 10.22 | -1.08 | 0.27 | -1.25 | 0.20 | |||||||
| CD8 | TG | 18.59 ± 6.11 | -0.64 | 0.51 | 21.13 ± 4.42 | -1.28 | 0.20 | 22.27 ± 14.24 | -0.61 | 0.53 | -1.01 | 0.31 | -0.66 | 0.50 |
| CG | 18.54 ± 3.51 | 19.01 ± 6.65 | 23.08 ± 12.81 | 0.00 | 1.00 | -0.78 | 0.43 | |||||||
| CD56 | TG | 20.52 ± 7.72 | -0.46 | 0.64 | 22.93 ± 5.21 | -0.05 | 0.95 | 20.18 ± 13.38 | -1.05 | 0.29 | -0.87 | 0.38 | -0.53 | 0.59 |
| CG | 18.58 ± 6.10 | 24.16 ± 10.93 | 23.00 ± 7.43 | -1.74 | 0.08 | -1.64 | 0.09 | |||||||
| CD71 | TG | 0.53 ± 0.24 | -0.09 | 0.92 | 3.52 ± 1.74 | -1.98 |
| 2.00 ± 1.54 | -1.45 | 0.14 | -3.18 |
| -2.94 |
|
| CG | 0.54 ± 0.30 | 2.23 ± 1.12 | 2.25 ± 0.75 | -3.11 |
| -3.06 |
| |||||||
| CD97 | TG | 0.77 ± 0.78 | -0.58 | 0.55 | 2.90 ± 1.79 | -2.46 |
| 2.63 ± 1.56 | -0.51 | 0.60 | -3.11 |
| -2.58 |
|
| CG | 0.69 ± 0.57 | 5.34 ± 2.96 | 2.33 ± 1.30 | -3.18 |
| -2.59 |
| |||||||
| CD134 | TG | 1.03 ± 0.49 | -0.97 | 0.32 | 0.28 ± 0.22 | -2.26 |
| 1.49 ± 0.93 | -0.33 | 0.73 | -2.97 |
| -0.48 | 0.62 |
| CG | 1.26 ± 0.44 | 0.63 ± 0.44 | 2.06 ± 2.48 | -2.83 |
| -0.40 | 0.68 | |||||||
| CD137 | TG | 0.14 ± 0.07 | -1.09 | 0.27 | 0.09 ± 0.07 | -2.25 |
| 0.63 ± 0.70 | -0.25 | 0.80 | -1.73 | 0.08 | -2.14 |
|
| CG | 0.18 ± 0.10 | 0.17 ± 0.09 | 1.19 ± 0.00 | 0.00 | 1.00 | -1.53 | 0.12 | |||||||
Note: Between-subject (Mann–Whitney U test) and within-subject (Wilcoxon’s T test) effects for immunological values at three assessment times. Means are expressed as percentages of total number of lymphoid cells. TG: Treatment Group; CG: Waitlist Control Group; M: Mean (SD: Standard Deviation); A: pre-treatment assessment; B: post-treatment assessment; C: three-month follow-up assessment.
Bold text: p < 0.05.